Homocysteine, methylenetetrahydrofolate reductase C677T polymorphism and cognitive impairment: The health in men study

Molecular Psychiatry

Volumn 17, Issue 5, 2012, Pages 559-566

  Ford, A H ^a   Flicker, L ^a   Hankey, G J ^b   Norman, P ^c   Van Bockxmeer, F M ^c   Almeida, O P ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

cognition; dementia; homocysteine; methylenetetrahydrofolate reductase gene

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); HOMOCYSTEINE;

ADULT; ARTICLE; COGNITIVE DEFECT; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN TISSUE; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; RISK; TELECONSULTATION;

AGED, 80 AND OVER; AGING; CASE-CONTROL STUDIES; COGNITION DISORDERS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HOMOCYSTEINE; HUMANS; MALE; MEN'S HEALTH; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84860167449     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2011.18     Document Type: Article

References (46)

1. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366: 2112-2117. (Pubitemid 41797645)
2. Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. BMJ 1998; 316: 894-898.
3. Smith AD. The worldwide challenge of the dementias: a role for B vitamins and homocysteine? Food Nutr Bull 2008; 29: S143-S172.
4. McCaddon A. Homocysteine and cognition-a historical perspective. J Alzheimers Dis 2006; 9: 361-380.
5. Nilsson K, Gustafson L, Faldt R, Andersson A, Brattstrom L, Lindgren A et al. Hyperhomocysteinaemia-a common finding in a psychogeriatric population. Eur J Clin Invest 1996; 26: 853-859. (Pubitemid 26343774)
6. Quadri P, Fragiacomo C, Pezzati R, Zanda E, Forloni G, Tettamanti M et al. Homocysteine, folate, and vitamin B-12 in mild cognitive impairment, Alzheimer disease, and vascular dementia. Am J Clin Nutr 2004; 80: 114-122. (Pubitemid 41115564)
7. Zylberstein DE, Lissner L, Bjorkelund C, Mehlig K, Thelle DS, Gustafson D et al. Midlife homocysteine and late-life dementia in women. A prospective population study. Neurobiol Aging 2009; e-pub 31 March 2009; doi:10.1016/j.neurobiolaging.2009.02.024.
8. Luchsinger JA, Tang MX, Shea S, Miller J, Green R, Mayeux R. Plasma homocysteine levels and risk of Alzheimer disease. Neurology 2004; 62: 1972-1976. (Pubitemid 38738206)
9. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002; 346: 476-483. (Pubitemid 34441738)
10. Stott DJ, MacIntosh G, Lowe GD, Rumley A, McMahon AD, Langhorne P et al. Randomized controlled trial of homocysteinelowering vitamin treatment in elderly patients with vascular disease. Am J Clin Nutr 2005; 82: 1320-1326. (Pubitemid 43779732)
11. Eussen SJ, de Groot LC, Joosten LW, Bloo RJ, Clarke R, Ueland PM et al. Effect of oral vitamin B-12 with or without folic acid on cognitive function in older people with mild vitamin B-12 deficiency: a randomized, placebo-controlled trial. Am J Clin Nutr 2006; 84: 361-370. (Pubitemid 44699146)
12. McMahon JA, Green TJ, Skeaff CM, Knight RG, Mann JI, Williams SM. A controlled trial of homocysteine lowering and cognitive performance. N Engl J Med 2006; 354: 2764-2772. (Pubitemid 43974194)
13. Durga J, van Boxtel MP, Schouten EG, Kok FJ, Jolles J, Katan MB et al. Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial. Lancet 2007; 369: 208-216. (Pubitemid 46107683)
14. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG. MTHFR 677C-7lt; T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA 2002; 288: 2023-2031. (Pubitemid 35204693)
15. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-113.
16. Elkins JS, Johnston SC, Ziv E, Kado D, Cauley JA, Yaffe K. Methylenetetrahydrofolate reductase C677T polymorphism and cognitive function in older women. Am J Epidemiol 2007; 166: 672-678. (Pubitemid 47347901)
17. McIlroy SP, Dynan KB, Lawson JT, Patterson CC, Passmore AP. Moderately elevated plasma homocysteine, methylenetetrahydrofolate reductase genotype, and risk for stroke, vascular dementia, and Alzheimer disease in Northern Ireland. Stroke 2002; 33: 2351-2356.
18. Bi XH, Zhao HL, Zhang ZX, Zhang JW. Association of RFC1 A80G and MTHFR C677T polymorphisms with Alzheimer's disease. Neurobiol Aging 2009; 30: 1601-1607.
19. Li K, Liu S, Yao S, Wang B, Dai D, Yao L. Interaction between interleukin-8 and methylenetetrahydrofolate reductase genes modulates Alzheimer's disease risk. Dement Geriatr Cogn Disord 2009; 27: 286-291.
20. Bottiglieri T, Parnetti L, Arning E, Ortiz T, Amici S, Lanari A et al. Plasma total homocysteine levels and the C677T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene: a study in an Italian population with dementia. Mech Ageing Dev 2001; 122: 2013-2023. (Pubitemid 32925111)
21. Almeida OP, Flicker L, Lautenschlager NT, Leedman P, Vasikaran S, van Bockxmeer FM. Contribution of the MTHFR gene to the causal pathway for depression, anxiety and cognitive impairment in later life. Neurobiol Aging 2005; 26: 251-257. (Pubitemid 39600581)
22. Hankey GJ, Eikelboom JW, Ho WK, van Bockxmeer FM. Clinical usefulness of plasma homocysteine in vascular disease. Med J Aust 2004; 181: 314-318. (Pubitemid 39302714)
23. Davey Smith G, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 2003; 32: 1-22. (Pubitemid 36503465)
24. Norman PE, Flicker L, Almeida OP, Hankey GJ, Hyde Z, Jamrozik K. Cohort Profile: The Health In Men Study (HIMS). Int J Epidemiol 2009; 38: 48-52.
25. Knopman DS, Roberts RO, Geda YE, Pankratz VS, Christianson TJ, Petersen RC et al. Validation of the telephone interview for cognitive status-modified in subjects with normal cognition, mild cognitive impairment, or dementia. Neuroepidemiology 2010; 34: 34-42.
26. Folstein MF, Folstein SE, McHugh PR. 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
27. Araki A, Sako Y. Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr 1987; 422: 43-52. (Pubitemid 17167357)
28. van Bockxmeer FM, Mamotte CD, Vasikaran SD, Taylor RR. Methylenetetrahydrofolate reductase gene and coronary artery disease. Circulation 1997; 95: 21-23. (Pubitemid 27029937)
29. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1982; 17: 37-49. (Pubitemid 13123113)
30. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
31. Rasmussen K, Moller J, Lyngbak M, Pedersen AM, Dybkjaer L. Age-and gender-specific reference intervals for total homocysteine and methylmalonic acid in plasma before and after vitamin supplementation. Clin Chem 1996; 42: 630-636. (Pubitemid 26111884)
32. Clarke R, Lewington S, Donald A, Johnston C, Refsum H, Stratton I et al. Underestimation of the importance of homocysteine as a risk factor for cardiovascular disease in epidemiological studies. J Cardiovasc Risk 2001; 8: 363-369. (Pubitemid 34107234)
33. Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 1998; 55: 1449-1455. (Pubitemid 28525506)
34. McCaddon A, Davies G, Hudson P, Tandy S, Cattell H. Total serum homocysteine in senile dementia of Alzheimer type. Int J Geriatr Psychiatry 1998; 13: 235-239. (Pubitemid 28194997)
35. Obeid R, Herrmann W. Mechanisms of homocysteine neurotoxicity in neurodegenerative diseases with special reference to dementia. FEBS Lett 2006; 580: 2994-3005. (Pubitemid 43744523)
36. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969; 56: 111-128.
37. Bostom AG, Silbershatz H, Rosenberg IH, Selhub J, D'Agostino RB, Wolf PA et al. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Arch Intern Med 1999; 159: 1077-1080. (Pubitemid 29230859)
38. Kloppenborg RP, van den Berg E, Kappelle LJ, Biessels GJ. Diabetes and other vascular risk factors for dementia: which factor matters most? A systematic review. Eur J Pharmacol 2008; 585: 97-108.
39. Bottiglieri T, Laundy M, Crellin R, Toone BK, Carney MW, Reynolds EH. Homocysteine, folate, methylation, and monoamine metabolism in depression. J Neurol Neurosurg Psychiatry 2000; 69: 228-232. (Pubitemid 30466029)
40. Sai X, Kawamura Y, Kokame K, Yamaguchi H, Shiraishi H, Suzuki R et al. Endoplasmic reticulum stress-inducible protein, Herp, enhances presenilin-mediated generation of amyloid beta-protein. J Biol Chem 2002; 277: 12915-12920. (Pubitemid 34952658)
41. Vafai SB, Stock JB. Protein phosphatase 2A methylation: a link between elevated plasma homocysteine and Alzheimer's disease. FEBS Lett 2002; 518: 1-4. (Pubitemid 34454953)
42. Perez FP, Ilie JI, Zhou X, Feinstein D, Jurivich DA. Pathomolecular effects of homocysteine on the aging process: a new theory of aging. Med Hypotheses 2007; 69: 149-160. (Pubitemid 46686939)
43. Armitage JM, Bowman L, Clarke RJ, Wallendszus K, Bulbulia R, Rahimi K et al. Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial. JAMA 2010; 303: 2486-2494.
44. Clarke R, Harrison G, Richards S. Effect of vitamins and aspirin on markers of platelet activation, oxidative stress and homocysteine in people at high risk of dementia. J Intern Med 2003; 254: 67-75. (Pubitemid 36819131)
45. Connelly PJ, Prentice NP, Cousland G, Bonham J. A randomised double-blind placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer's disease. Int J Geriatr Psychiatry 2008; 23: 155-160. (Pubitemid 351308495)
46. Lewerin C, Matousek M, Steen G, Johansson B, Steen B, Nilsson-Ehle H. Significant correlations of plasma homocysteine and serum methylmalonic acid with movement and cognitive performance in elderly subjects but no improvement from short-term vitamin therapy: a placebo-controlled randomized study. Am J Clin Nutr 2005; 81: 1155-1162. (Pubitemid 41724959)